Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma

Dono, Antonio; Zhu, Ping; Holmes, Emma; Takayasu, Takeshi; Zhu, Jay‐Jiguang; Blanco, Angel I.; Hsu, Sigmund; Bhattacharjee, Meenakshi B.; Ballester, Leomar Y.; Esquenazi, Yoshua; Tandon, Nitin

doi:10.1007/s11060-021-03917-1

Cited by 4 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the small numbers of participants, both results should be interpreted with caution and should not be generalized. It is also noted that in clinical practice, only a small subset of patients with GBM are eligible for additional surgery at the time of recurrence, typically representing smaller tumors, younger patients with better performance status, and greater initial resection [31].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Şener

Ruff

Campian

2022

IJMS

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields, recurrence is universal, median observed survival is low at 8 months and 5-year overall survival is poor at 7%. Immunotherapy aims to generate a tumor-specific immune response to selectively eliminate tumor cells. In treatment of GBM, immunotherapy approaches including use of checkpoint inhibitors, chimeric antigen receptor (CAR) T-Cell therapy, vaccine-based approaches, viral vector therapies, and cytokine-based treatment has been studied. While there have been no major breakthroughs to date and broad implementation of immunotherapy for GBM remains elusive, multiple studies are underway. In this review, we discuss immunotherapy approaches to GBM with an emphasis on molecularly informed approaches.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Şener

Ruff

Campian

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…2,3 Treatment for these tumors includes maximal-safe resection and chemoradiotherapy with temozolomide according to the Stupp protocol, 4 and recurrent glioblastoma treatment includes reoperation, reirradiation, multiple different chemotherapy options, and tumortreating fields. [5][6][7][8] Readmission of patients within 30 days of surgery is thought to delay adjuvant therapies and, therefore, decrease survival. 9 Furthermore, unplanned readmissions are an important factor in the financial and resource burden for the health care system.…”

mentioning

confidence: 99%

Commentary: Predictors and Impact of Postoperative 30-Day Readmission in Glioblastoma

2022

Self Cite

View full text Add to dashboard Cite

Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background The value of re-resection in recurrent glioblastoma remains controversial as a randomized trial that specifies intentional incomplete resection cannot be justified ethically. Here, we aimed to (1) explore the prognostic role of extent of re-resection using the previously proposed Response Assessment in Neuro-Oncology (RANO) classification (based upon residual contrast-enhancing (CE) and non-CE tumor), and to (2) define factors consolidating the surgical effects on outcome. Methods The RANO resect group retrospectively compiled an 8-center cohort of patients with first recurrence from previously resected glioblastomas. The associations of re-resection and other clinical factors with outcome were analyzed. Propensity score-matched analyses were constructed to minimize confounding effects when comparing the different RANO classes. Results We studied 681 patients with first recurrence of Isocitrate Dehydrogenase (IDH) wild-type glioblastomas, including 310 patients who underwent re-resection. Re-resection was associated with prolonged survival even when stratifying for molecular and clinical confounders on multivariate analysis; ≤1 cm3 residual CE tumor was associated with longer survival than non-surgical management. Accordingly, “maximal resection” (class 2) had superior survival compared to “submaximal resection” (class 3). Administration of (radio-)chemotherapy in the absence of postoperative deficits augmented the survival associations of smaller residual CE tumors. Conversely, “supramaximal resection” of non-CE tumor (class 1) was not associated with prolonged survival but was frequently accompanied by postoperative deficits. The prognostic role of residual CE tumor was confirmed in propensity score analyses. Conclusions The RANO resect classification serves to stratify patients with re-resection of glioblastoma. Complete resection according to RANO resect classes 1 and 2 is prognostic.

show abstract

Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma

Cited by 4 publications

References 44 publications

Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

Commentary: Predictors and Impact of Postoperative 30-Day Readmission in Glioblastoma

Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group

Contact Info

Product

Resources

About